In ₹ Crore except Per Share Latest Annual | CAPLIPOINT FY26 | AJANTPHARM FY26 | ERIS FY26 | GLAND FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 33.10× | 41.88× | ◆ 29.96× | 47.31× | 41.88× -21% | |
| P/B | 5.84× | 9.80× | 4.83× | ◆ 4.69× | 4.83× +21% | |
| EV/EBITDA | 27.26× | 31.49× | ◆ 18.80× | 27.91× | 27.91× -2% | |
| Market Cap | ₹21,219 Cr | ₹44,374 Cr | ₹18,808 Cr | ₹48,604 Cr | ₹44,374 Cr -52% | |
| Growth | ||||||
| Revenue CAGR 3Y | 14.25% | 13.37% | ◆ 22.92% | 21.06% | 21.06% -32% | |
| Revenue CAGR 5Y | 15.56% | 13.54% | ◆ 20.89% | 13.18% | 13.54% +15% | |
| Net Income CAGR 3Y | 19.89% | ◆ 21.55% | 20.06% | 9.57% | 20.06% -1% | |
| Revenue YoY (latest Q) | 19.63% | ◆ 24.82% | 12.97% | 19.57% | 19.57% +0% | |
| Net Income YoY (latest Q) | 18.79% | 30.89% | 14.56% | ◆ 47.09% | 30.89% -39% | |
| Profitability | ||||||
| EBITDA Margin | 34.79% | 25.58% | ◆ 35.79% | 25.34% | 25.58% +36% | |
| Net Income Margin | ◆ 29.71% | 19.37% | 20.69% | 15.98% | 19.37% +53% | |
| Return on Common Equity | 17.66% | ◆ 23.33% | 15.90% | 9.92% | 15.90% +11% | |
| Return on Capital Employed | 18.80% | ◆ 25.78% | 15.90% | 11.06% | 15.90% +18% | |
| Return on Assets | 16.06% | ◆ 17.16% | 8.79% | 8.21% | 8.79% +83% | |
| Credit & Quality | ||||||
| Total Debt/Equity | ◆ 0.00× | 0.05× | 0.59× | 0.02× | 0.05× -100% | |
| Interest Coverage | ◆ 790.90× | 75.83× | 4.36× | 36.24× | 36.24× +2082% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹2,187 Cr | ₹5,453 Cr | ₹3,129 Cr | ₹6,431 Cr | ₹5,453 Cr -60% | |
| Net Income | ₹650 Cr | ₹1,056 Cr | ₹648 Cr | ₹1,027 Cr | ₹1,027 Cr -37% | |
| Total Assets | ₹4,045 Cr | ₹6,155 Cr | ₹7,366 Cr | ₹12,511 Cr | ₹7,366 Cr -45% | |
| EPS | ₹84.36 | ₹84.53 | ₹45.33 | ₹62.35 | ₹62.35 +35% | |
| Book Value per Share | ₹477.74 | ₹361.16 | ₹281.28 | ₹628.67 | ₹361.16 +32% | |